Amyloidosis awareness is only the beginning
Posted by: Alexandros Marantzidis
World Amyloidosis Day may have passed, but the conversation it creates should continue.
Amyloidosis is a complex disease that rarely sits neatly within one area of medicine. Its diagnosis, treatment and ongoing management can involve several different specialties, each bringing an important piece of the picture. Delivering truly coordinated care depends on bringing those pieces, and those people, together.
That is why awareness, while essential, is only the beginning.
Awareness must lead to stronger clinical pathways, closer collaboration and services that connect the right expertise around each patient. Yet establishing and sustaining this kind of multidisciplinary care is not always straightforward. Healthcare teams may need to strengthen referral pathways, build the case for institutional support, secure appropriate resources and develop more effective ways of working across specialties.
Our independent medical education program, Amyloidosis Action*, was created with these real-world challenges in mind. It supports healthcare professionals who are working to establish a specialist amyloidosis service, as well as teams looking to strengthen an existing center.
Explore the Amyloidosis Action program*
Explore the programRather than focusing on theory alone, the program shares practical insights and experiences from amyloidosis experts and centers around the world. Through interactive, case-based learning, center success stories, multidisciplinary team interviews, roundtable reports and practical resources, it explores what coordinated amyloidosis care can look like in different healthcare settings.
It also recognizes that there is no single model that can simply be applied everywhere. Every healthcare environment has its own structure, barriers and patient needs. What can be shared, however, is experience. Learning from teams that have already navigated similar challenges can help others identify what meaningful progress might look like within their own setting.
World Amyloidosis Day gives us an important moment to focus attention on the disease.
The greater ambition is to carry that momentum forward, helping more patients access timely diagnosis and coordinated specialist care.
_____________________________________________________________________
*AstraZeneca and Alexion, AstraZeneca Rare Disease have provided an unrestricted educational grant towards this independent program.